Table 4 FDR Significant and Cross-Validated Epistatic Effects of ADRA2C and ADRB1 polymorphisms on survival

Main Effects

ADRA2C (-1692 T/G)

TT

1

544

0.029

0.031

TG

1.34(0.91, 1.95)

74

GG

n/a

6

ADRA2C (+964 ins/del)

11

1

516

0.065

0.018

10

0.51(0.07, 3.64)

65

00

1.58(1.07, 2.32)*

6

Epistatic Effects

ADRA2C (+964 ins/del)

ADRB1 (+145 A/G)

00

AA

n/a

5

<0.001

0.069

10

AA

1.20 (0.74,1.95)

39

10

AG

5.12 (2.66, 9.88)*

17

11

AA

1

349

11

AG

0.86 (0.59, 1.25)

108

11

GG

0.70 (0.31, 1.61)

15

ADRA2C (-230 T/C)

ADRB1 (-517 T/C)

TC

CT

8.31(3.32, 20.75)*

7

<0.001

<0.001

TC

TT

0.46(0.15, 1.42)

16

TT

CC

0.51(0.21,1.24)

17

TT

CT

0.88 (0.62,1.26)

121

TT

TT

1

455

ADRA2C (-230 T/C)

ADRB1 (-2297 T/G)

TC

TG

9.23(3.67,23.16)*

7

0.001

0.014

TC

TT

0.61(0.22, 1.64)

16

TT

GG

0.61(0.27,1.38)

18

TT

TG

0.99 (0.71,1.36)

137

TT

TT

1

422

ADRA2C (-1692 T/G)

ADRB1 (+145 A/G)

GG

AA

n/a

5

0.001

0.097

TG

AA

0.99 (0.62,1.61)

44

TG

AG

4.59 (2.31,9.12)*

17

TG

GG

n/a

2

TT

AA

1

371

TT

AG

0.85(0.59, 1.22)

111

TT

GG

0.61(0.27, 1.38)

17

ADRA2C (-1692 T/G)

ADRB1 (-3641 C/T)

GG

CC

n/a

6

0.005

<0.001

TG

CC

0.95 (0.60, 1.53)

52

TG

CT

3.56 (1.80,7.05)*

18

TT

CC

1

369

TT

CT

0.84 (0.58,1.21)

116

TT

TT

0.62 (0.27, 1.42)

17

ADRA2C (-1692 T/G)

ADRB1 (-3255 A/C)

GG

AA

n/a

6

0.010

<0.001

TG

AA

1.08 (0.68,1.71)

52

TG

AC

3.02(1.53,5.97)*

19

TT

AA

1

379

TT

AC

0.83(0.58,1.21)

116

TT

CC

0.73 (0.32,1.66)

16